7th June2026: RIYADH, SAUDI ARABIA: Jamjoom Pharma, a leading Saudi pharmaceutical healthcare company in the Middle East and Africa (MEA), has officially signed a Memorandum of Understanding (MoU) with the General Administration of Pharmaceutical Care at the Ministry of Health, Saudi Arabia. This strategic partnership aims to support the development of healthcare and pharmaceutical professionals through structured training programs and educational initiatives, ultimately enhancing the quality of healthcare services and driving the objectives of Saudi Vision 2030.
The agreement aligns with Jamjoom Pharma’s broader corporate strategy to solidify its role as an active national partner in advancing the domestic healthcare sector. This is achieved by investing directly in local healthcare and pharmaceutical talent development, supporting community health awareness programs, and expanding robust collaborations with government health entities.
Under the terms of the MoU, Jamjoom Pharma and the General Administration of Pharmaceutical Care will collaborate on implementing developmental programs across specialized administrative, technical, and professional fields. The partnership will also focus on designing and developing educational curriculums that meet global professional standards, alongside organizing specialized workshops, seminars, and forums dedicated to pharmaceutical training. Furthermore, the collaboration will encompass assessing the specific training needs of healthcare practitioners (HCPs), providing professional consultations, evaluating the long-term impact of these training initiatives, and exchanging expertise in professional development.
The MoU was signed by Dr. Ahmed Samir Al Khouly, General Manager at Jamjoom Pharma Saudi Arabia, and Dr. Mohammed Alshennawi, General Director of the General Administration of Pharmaceutical Care at the Ministry of Health, KSA, in the presence of senior officials from both organizations.
Commenting on the partnership, Dr. Ahmed Samir Al Khouly, General Manager at Jamjoom Pharma Saudi Arabia, stated:
“The MoU with the Ministry of Health’s General Administration of Pharmaceutical Care reflects Jamjoom Pharma’s deep commitment to supporting the development of local pharmaceutical competencies and enhancing specialized professional training programs. This initiative will empower healthcare practitioners to stay at the forefront of the latest advancements in the medical and pharmaceutical sectors, while actively supporting the Kingdom’s healthcare transformation goals.”
For his part, Dr. Mohammed Alshennawi, General Director of the General Administration of Pharmaceutical Care at the Ministry of Health, KSA, added:
“This agreement marks a significant step forward in nurturing the development of our pharmaceutical professionals. By establishing specialized training programs and advanced learning environments, we promote continuous professional development and enhance performance efficiency, all in partnership with one of the nation’s leading healthcare companies.”
This agreement underscores Jamjoom Pharma’s ongoing dedication to public health, education, and community-centric initiatives. It reinforces the company’s role as an impactful partner in advancing Saudi Arabia’s healthcare landscape through sustainable strategic partnerships with government bodies, fostering stronger integration between the public and private sectors to deliver on the Kingdom’s national healthcare transformation objectives.
Jamjoom Pharma operates in more than 37 countries across the Middle East and Africa, with its core operations anchored in Saudi Arabia, the UAE, Iraq, the Levant, Egypt, and North Africa. The company has secured a market-leading position as a trusted provider of high-quality medicines and consumer healthcare products across multiple therapeutic segments, including ophthalmology, dermatology, cardio-metabolic diseases, and general medicine.
– ENDS –
